CLINICAL ROLE -
ERLEADA for Prostate Cancer
On February 14, 2018, the FDA approved apalutamide (Erleada) by Janssen Biotech Inc for the treatment of nonmetastatic castration-resistant prostate cancer (NM-CRPC).
Read More